News
-
-
COMMUNIQUÉ DE PRESSE
MindBio Therapeutics Reports Sustained Antidepressant Response from MB22001 in Depression Clinical Trials
MindBio Therapeutics Corp. reports Phase 2A clinical trials results showing substantial and sustained reduction in depression symptoms with MB22001, a self-administered microdose of LSD -
COMMUNIQUÉ DE PRESSE
MindBio Therapeutics Reports Sustained Antidepressant Response from MB22001 in Depression Clinical Trials
MindBio Therapeutics reports significant and sustained reduction in depression symptoms with MB22001 microdosing trials. Phase 2B trials show promise for mental health treatment -
-
-
COMMUNIQUÉ DE PRESSE
MindBio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial
MindBio Therapeutics Corp. reports positive secondary data from groundbreaking depression trial using microdoses of psychedelic medicines, showing significant improvements in anxiety, stress, and depression levels -
COMMUNIQUÉ DE PRESSE
MindBio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial
MindBio Therapeutics Corp. reports positive secondary data from groundbreaking microdosing depression trial with MB22001, showing significant reductions in anxiety, stress, and depression -
-
-
COMMUNIQUÉ DE PRESSE
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
MindBio to develop novel psilocin prodrug from Enveric Biosciences for neuropsychiatric indications, utilizing microdosing to minimize hallucinogenic effects of psychedelic compounds
